A randomised double blind controlled trial of BCNU [carmustine] as second line therapy in metastatic oesophago [oesophageal]-gastric, colorectal and pancreatic cancer

Trial Profile

A randomised double blind controlled trial of BCNU [carmustine] as second line therapy in metastatic oesophago [oesophageal]-gastric, colorectal and pancreatic cancer

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Carmustine (Primary)
  • Indications Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Aug 2009 Actual initiation date (Jan 1995 ) added as reported by ISRCTN: Current Controlled Trials.
    • 16 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top